- Home
- CMPX vs FLC Comparison
CMPX vs FLC Comparison
Compare CMPX & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- FLC
- Stock Information
- Founded
- CMPX 2014
- FLC 2003
- Country
- CMPX United States
- FLC United States
- Employees
- CMPX N/A
- FLC N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- CMPX Health Care
- FLC Finance
- Exchange
- CMPX Nasdaq
- FLC Nasdaq
- Market Cap
- CMPX 291.8M
- FLC 174.2M
- IPO Year
- CMPX N/A
- FLC N/A
- Fundamental
- Price
- CMPX $2.65
- FLC $17.17
- Analyst Decision
- CMPX Strong Buy
- FLC
- Analyst Count
- CMPX 9
- FLC 0
- Target Price
- CMPX $12.67
- FLC N/A
- AVG Volume (30 Days)
- CMPX 797.6K
- FLC 37.8K
- Earning Date
- CMPX 08-11-2025
- FLC 01-01-0001
- Dividend Yield
- CMPX N/A
- FLC 6.64%
- EPS Growth
- CMPX N/A
- FLC N/A
- EPS
- CMPX N/A
- FLC N/A
- Revenue
- CMPX $850,000.00
- FLC N/A
- Revenue This Year
- CMPX N/A
- FLC N/A
- Revenue Next Year
- CMPX N/A
- FLC N/A
- P/E Ratio
- CMPX N/A
- FLC N/A
- Revenue Growth
- CMPX N/A
- FLC N/A
- 52 Week Low
- CMPX $0.87
- FLC $12.62
- 52 Week High
- CMPX $4.08
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- CMPX 64.52
- FLC 68.17
- Support Level
- CMPX $2.62
- FLC $16.86
- Resistance Level
- CMPX $2.87
- FLC $17.12
- Average True Range (ATR)
- CMPX 0.16
- FLC 0.12
- MACD
- CMPX 0.00
- FLC 0.01
- Stochastic Oscillator
- CMPX 81.03
- FLC 100.00
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.